Characteristics of Gastric Carcinomas With High ERCC1 Expression and the Prognostic Value of ERCC1 Expression

Yang, Jung Wook; Lee, Jeong-Hee; Lee, Jong Sil; Kim, Dong Chul; Song, Dae Hyun; Jang, Sang Ock; An, Hyo Jung; Koh, Hyun Min; Kim, Minhye; Na, Ji Min; Jeong, Sang‐Ho; Lee, Young-Joon; Ko, Gyung Hyuck

doi:10.21873/anticanres.14301

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Patients with ERCC1-high gastric carcinoma had a lower cumulative incidence function estimate of cancer-related death [3.37; 95 percent (CI)=0.89-8.75] than those with ERCC1-low gastric carcinoma (17.12; 95 percent CI=12.24-22.69; p-value by Gray's test=0.0012) than those with ERCC1-low gastric carcinoma (17.12; 95 percent CI=12. 24-22.69; p-value The adjusted proportional sub-distribution hazard ratio for cancer-related death in patients with ERCC1-high tumors was 0.272 (95 percent CI=0.084-0.878; p=0.0295) [31].…”

Section: Discussionmentioning

confidence: 95%

ERCC1 and claudin-4 expression in gastric cancer tumorogenesis and development have clinical and pathological relevance.

2021

SECI Oncology Journal

View full text Add to dashboard Cite

Background: Gastric cancer is a significant health and social problem with a high risk of local recurrence. The goal of this study was to look at the immunohistochemistry expression of ERCC1 and claudin-4 in gastric cancer, as well as the relationship with clinicopathologic items and survival in gastric cancer, in order to see how these proteins affect progression and tumorogenesis. Materials and methods: A total of 155 postoperative specimens were collected, analyzed, and utilized to create tissue microarray blocks from patients diagnosed with stomach cancer. Claudin-4 and ERCC1 immunohistochemical expression were investigated and their relationship with clinicopathological characteristics and patient prognosis was determined. Results: Claudin-4 and ERCC1 were found in gastric cancer tissues in 54.2 percent and 41.3 percent, respectively. Both proteins were shown to be associated with TNM stage, the number of positive lymph nodes (N), and the depth of invasion (T). Despite the fact that ERCC1 had a strong relationship with histological type and grade, as well as Lauren categorization, claudin-4 did not. High claudin-4 expression was linked to a greater survival rate (58.9%) and an increase in OS (24.5 months) and DFS (18.9 months) in the survival study, but ERCC1 had no correlation with life expectancy (except for DFS on multivariate analysis). Conclusion:The findings of this retrospective analysis show that the ERCC1 gene polymorphism and Claudin-4 have a significant impact on gastric cancer pharmacokinetics and treatment outcome. Also it may be useful biomarkers to predict the clinical outcomes and can select the cases who receive more aggressive protocols.

show abstract

Section: Discussionmentioning

confidence: 95%

ERCC1 and claudin-4 expression in gastric cancer tumorogenesis and development have clinical and pathological relevance.

2021

SECI Oncology Journal

View full text Add to dashboard Cite

show abstract

“…A study in hepatocellular carcinoma (HCC) patients showed that the level of ERCC1 in the cancer tissues was significantly lower than that in adjacent paracancer tissues and that the expression of ERCC1 was negatively associated with hepatic capsular and microvascular invasion [ 25 ]. The difference concerning the expression of ERCC1 in several cancers may be due to the different types of cancer and/or the different roles of ERCC1 in these various tumors.…”

Section: Discussionmentioning

confidence: 99%

Expression and Genetic Polymorphisms of ERCC1 in Chinese Han Patients with Oral Squamous Cell Carcinoma

Wang

Gan

Liu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

The aim of this study was to investigate the expression of the excision repair cross-complementation group 1 (ERCC1) in oral squamous cell carcinoma (OSCC) and the possible association of ERCC1 polymorphisms with susceptibility and response to chemotherapy of OSCC in a Chinese Han population. The expression of ERCC1 was determined by real-time PCR in eight patients. Four single-nucleotide polymorphisms (SNPs) rs11615, rs3212948, rs3212961, and rs735482 of ERCC1 were genotyped in 113 OSCC patients and 184 healthy controls using a PCR restriction matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) assay. We found that a higher gene expression of ERCC1 was observed in tumor tissue as compared to pericarcinomatous tissue in OSCC patients. All genotypic and allelic frequencies of the tested ERCC1 polymorphisms were in Hardy-Weinberg equilibrium. The genotypic and allelic frequencies of rs11615, rs3212948, rs3212961, and rs735482 of ERCC1 were not different between OSCC patients and controls. No correlation was observed between ERCC1 polymorphisms and the response to chemotherapy. Our results show that ERCC1 is increased in the tumor tissue of OSCC patients. The investigated ERCC1 gene polymorphisms (rs11615, rs3212948, rs3212961, and rs735482) are not associated with the susceptibility and response to chemotherapy of OSCC in our investigated Chinese Han population.

show abstract

Characteristics of Gastric Carcinomas With High ERCC1 Expression and the Prognostic Value of ERCC1 Expression

Cited by 2 publications

References 9 publications

ERCC1 and claudin-4 expression in gastric cancer tumorogenesis and development have clinical and pathological relevance.

ERCC1 and claudin-4 expression in gastric cancer tumorogenesis and development have clinical and pathological relevance.

Expression and Genetic Polymorphisms of ERCC1 in Chinese Han Patients with Oral Squamous Cell Carcinoma

Contact Info

Product

Resources

About